株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

プレフィルシリンジ:世界市場の見通し

Global Pre-Filled Syringes Market Forecast 2017-2027: Glass Pre-Filled Syringes, Plastic Pre-Filled Syringes, Pen Injectors and Autoinjectors

発行 Visiongain Ltd 商品コード 206673
出版日 ページ情報 英文 211 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=148.88円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
プレフィルシリンジ:世界市場の見通し Global Pre-Filled Syringes Market Forecast 2017-2027: Glass Pre-Filled Syringes, Plastic Pre-Filled Syringes, Pen Injectors and Autoinjectors
出版日: 2017年03月31日 ページ情報: 英文 211 Pages
概要

世界のプレフィルシリンジ市場は、2021年に76億2,900万米ドルの規模に達する見込みで、2016年から2027年までCAGR9.7%の安定した成長を続け、2027年には127億6,400万米ドルに達すると予測されています。

当レポートでは、世界のプレフィルシリンジ市場について調査分析し、市場の収益予測(今後11年間分)や、成長率、市場シェア、技術動向、製品別・地域別・治療分野別の詳細動向・予測、今後の市場の機会と課題などについてまとめてお届けいたします。

第1章 レポート概要

第2章 プレフィルシリンジ市場のイントロダクション

  • プレフィルシリンジとは?
  • プレフィルシリンジの略史
  • プレフィルシリンジの設計と製造
  • ペン型注射器・オートインジェクターの概略
  • ガラス製とプラスチック製
  • プレフィルシリンジの今後の方向性
  • 市場区分
  • 調査範囲
  • 本レポートにおける為替レート

第3章 世界市場の見通しと予測

  • 世界のドラッグデリバリー市場におけるシェア
  • 世界のプレフィルシリンジ市場
  • 価格ベースの売上予測
  • セグメント別市場シェア予測
  • 成長促進因子と抑制因子
  • ガラス製プレフィルシリンジ市場の予測
  • プラスチック製プレフィルシリンジ市場の予測
  • ペン型注射器・オートインジェクター市場の予測

第4章 主要国市場の予測

  • 世界のプレフィルシリンジ市場:国別内訳
  • 主要国のプレフィルシリンジ市場
  • 世界のプレフィルシリンジ市場:地域別内訳
  • 地域別市場予測
  • 米国のプレフィルシリンジ市場の予測
  • 日本のプレフィルシリンジ市場の予測
  • EU5ヵ国のプレフィルシリンジ市場の予測
  • 新興国のプレフィルシリンジ市場(中国・インド・ロシア・ブラジル)

第5章 プレフィルシリンジの主な治療分野の見通し

  • プレフィルシリンジおよび他の注射装置の主な治療分野
  • 糖尿病向けプレフィルシリンジおよびペン型注射器:市場予測
  • リウマチ性関節炎
  • 成長ホルモン:市場展望
  • ワクチン:市場展望
  • PCSK9 インヒビター:市場予測

第6章 プレフィルを用いる代表的な治療方法

  • ペン型注射器を用いる主なインスリン療法
    • Lantus:世界的ベストセラーのインスリン類似体
    • NovoLog:代表的な即効性インスリン
    • Humalog
  • リウマチ性関節炎向けの主な生物製剤:市場展望
    • Humira:世界最大の売上高となった薬剤
    • Enbrel:Humiraの最大のライバル
  • 成長ホルモン市場:2種類の医薬品による独占状態
    • Norditropin
    • Genotropin
  • PCSK9 製品:市場の見通し
    • Praluent (alirocumab, Sanofi/Regeneron)
    • Repatha (evolocumab, Amgen)

第7章 プレフィルシリンジおよび関連製品の主要メーカー

  • 代表的なプレフィルシリンジメーカー
    • Becton, Dickinson & Company:最大の市場リーダー
    • Gerresheimer
    • Schott
  • その他の注目すべきプレフィルシリンジメーカー
  • 代表的なペン型注射器・オートインジェクターメーカー
    • SHL Group
    • Ypsomed
    • Haselmeier
    • Owen Mumford
    • Bespak:新規参入者
    • その他
  • 代表的なプレフィルシリンジ用部品メーカー
    • Datwyler

第8章 プレフィルシリンジ市場の定量分析

  • SWOT分析(強み、弱み、機会、脅威)
  • STEP分析(社会的・技術的・経済的・政治的要因)
  • 規制面・安全面での見通し
  • 生物製剤とプレフィルシリンジ市場の見通し
  • プレフィルシリンジ産業の発展・成長における患者の役割
  • プレフィルシリンジの技術開発の見通し
  • プレフィルシリンジ産業におけるアウトソーシング

第9章 分析の結論

第10章 用語集

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0180

The global pre-filled syringes market is expected to grow at a moderate growth rate over the forecast period. The global pre-filled syringes market was valued at $4,663m in 2016. Visiongain forecasts this market to increase to $7,629m in 2021. The market will then continue to increase to $12,764m in 2027, growing at a CAGR of 9.7% between 2016 and 2027.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new report you find 211-page report you will receive 68 tables and 55 figures - all unavailable elsewhere.

The 211-page report provides clear detailed insight into the global pre-filled syringes market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Global Pre-Filled Syringes market forecasts from 2017-2027
  • Pre-Filled Syringes national market forecasts from 2017-2027, covering:
    • United States
    • Japan
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Brazil
    • Russia
    • India
    • China
  • Pre-Filled Syringes submarket forecasts from 2017-2027 covering:
    • Glass Pre-Filled Syringes
    • Pen Injectors and Autoinjectors
    • Plastic Pre-Filled Syringes
  • Forecasts from 2017-2027 of the leading therapeutic sectors for the Pre-Filled Syringes market:
    • Insulin Therapies
    • Rheumatoid Arthritis (RA) Therapies
    • Growth Hormones
    • Vaccines
    • PCSK9 Inhibitors
  • Forecasts from 2017-2027 of the leading pre-filled devices:
    • Lantus
    • NovoRapid/Novolog
    • Humalog
    • Humira
    • Enbrel
    • Norditropin
    • Genotropin
    • Praluent
    • Repatha
  • Assessment of the leading pre-filled syringes manufacturers and related technology manufacturers
  • SWOT and STEP analysis

Visiongain's study is intended for anyone requiring commercial analyses for the Pre-Filled Syringes Market and leading companies. You find data, trends and predictions.

Buy our report today Global Pre-Filled Syringes Market Forecast 2017-2027: Glass Pre-Filled Syringes, Plastic Pre-Filled Syringes, Pen Injectors and Autoinjectors.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Pre-Filled Syringes Market Overview
  • 1.2. Global Pre-Filled Syringes Market Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered by This Analytical Report
  • 1.6. Who is This Report For?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Visiongain Reports
  • 1.10. About Visiongain

2. Introduction to Pre-Filled Syringes

  • 2.1. What are Pre-Filled Syringes?
  • 2.2. A Brief History of Pre-Filled Syringes
  • 2.3. Design and Manufacture of Pre-Filled Syringes
    • 2.3.1. Glass and Plastic Syringes
    • 2.3.2. Safety and the Pre-Filled Syringe Market
    • 2.3.3. Concerns over Needlestick Injuries
  • 2.4. An Introduction to Pen Injectors and Autoinjectors
    • 2.4.1. Pen Injectors and Autoinjectors Offer Advantages in Self-Administration
    • 2.4.2. What Determines Injection Device Choice?
  • 2.5. Glass versus Plastic
    • 2.5.1. Glass
    • 2.5.2. Plastic
  • 2.6. Future Directions for Pre-Filled Syringes
  • 2.7. Pre-Filled Syringes: Market Segmentation
  • 2.8. Scope of this Report
    • 2.8.1. Products Excluded from this Report
  • 2.9. Currency Exchange Rates in This Report

3. Pre-Filled Syringes: World Market 2017-2027

  • 3.1. Pre-Filled Syringes as a Share of the Global Drug Delivery Market
  • 3.2. The World Pre-Filled Syringes Market in 2016
    • 3.2.1. World Pre-Filled Syringes Market: Market Shares by Segment 2016
    • 3.2.2. Leading Companies in the Pre-Filled Syringes Market
  • 3.3. World Pre-Filled Syringes Market: Sales Forecast by Value, 2017-2027
  • 3.4. How Will Segmental Market Shares Change to 2027?
  • 3.5. World Pre-Filled Syringes Market: Drivers and Restraints 2017-2027
    • 3.5.1. Biologics and Biosimilars to Drive Market Growth
    • 3.5.2. Human Factors and Regulatory Requirements
    • 3.5.3. Advances in Pre-Filled Syringe Manufacturing
    • 3.5.4. Market Genericisation and Pre-Filled Syringes
    • 3.5.5. The Injectable Drug Pipeline is Substantial
    • 3.5.6. Competing Drug Delivery Technologies
  • 3.6. Glass Pre-Filled Syringes Lead the Pre-Filled Syringes Market
    • 3.6.1. Glass Pre-Filled Syringes Market: Sales Forecast by Value, 2017-2027
    • 3.6.2. Glass Pre-Filled Syringes: Drivers and Restraints 2017-2027
  • 3.7. Plastic Pre-Filled Syringes: Rapid Growth Forecasted
    • 3.7.1. Plastic Pre-Filled Syringes Market: Sales Forecast by Revenue, 2017-2027
    • 3.7.2. Plastic Pre-Filled Syringes: Drivers and Restraints 2017-2027
  • 3.8. Pen Injectors and Autoinjectors: A Growing Segment
    • 3.8.1. Pen Injectors and Autoinjectors Market: Sales Forecast by Value, 2017-2027
    • 3.8.2. Pen Injectors and Autoinjectors: Drivers and Restraints 2017-2027
    • 3.8.3. Insulin and Other Biologics to Lead Market Growth

4. Leading National and Regional Markets 2017-2027

  • 4.1. National Breakdown of the World Pre-Filled Syringes Market
  • 4.2. World Pre-Filled Syringes Market: National Markets Forecast 2017-2027
    • 4.2.1. How Will National Market Shares Change to 2027?
  • 4.3. Regional Breakdown of the World Pre-Filled Syringes Market
  • 4.4. World Pre-Filled Syringes Market: Regional Markets Forecast 2017-2027
    • 4.4.1. How Will Regional Market Shares Change to 2027?
  • 4.5. US Pre-Filled Syringes Market Forecast 2017-2027
    • 4.5.1. US Pre-Filled Syringes Market: Trends and Developments
      • 4.5.1.1. New Drug and Device Launches to Drive Growth to 2027
      • 4.5.1.2. The Budget Control Act 2011 and the Medical Excise Tax
  • 4.6. Japanese Pre-Filled Syringes Market Forecast 2017-2027
  • 4.7. EU5 Pre-Filled Syringes Market Forecast 2017-2027
  • 4.8. Emerging Markets: Pre-Filled Syringes Market Forecast 2017-2027
    • 4.8.1. Pre-Filled Syringe Manufacturers Are Investing in Emerging Markets
    • 4.8.2. Chinese Pre-Filled Syringes Market Forecast 2017-2027
    • 4.8.3. Indian Pre-Filled Syringes Market Forecast 2017-2027
    • 4.8.4. Russian Pre-Filled Syringes Market Forecast 2017-2027
    • 4.8.5. Brazilian Pre-Filled Syringes Market Forecast 2017-2027

5. Leading Therapeutic Sectors for Pre-Filled Syringes 2017-2027

  • 5.1. Leading Therapeutic Sectors for Pre-Filled Syringes and Other Injection Devices in 2016
    • 5.1.1. Vaccines and Heparins Are Major Market Sectors
    • 5.1.2. Rising Demand in Chronic Conditions: Autoimmune Diseases and Diabetes
    • 5.1.3. Growth for Key Market Sectors 2017-2027
  • 5.2. Pre-Filled Syringes and Pen Injectors for Diabetes 2017-2027
    • 5.2.1. Insulin Market Forecast 2017-2027
    • 5.2.2. High Rates of Pen Injector Use in the EU and Japan
    • 5.2.3. Insulin Pumps: A Technology to Challenge Pen Injectors to 2027?
    • 5.2.4. MannKind's Afrezza: Inhalable Insulin Approved in US
    • 5.2.5. Injection Devices for Biosimilar Insulin Products
  • 5.3. Rheumatoid Arthritis: Leading Biologics Dominate the Market
    • 5.3.1. Rheumatoid Arthritis Market Forecast 2017-2027
    • 5.3.2. All Major Injectable Therapies Are Marketed in Proprietary Devices
    • 5.3.3. Novel Injection Systems for RA: Meeting the Needs of Patients
    • 5.3.4. The Receding Threat from Oral Therapies to 2027
  • 5.4. Growth Hormones: Outlook to 2027
    • 5.4.1. Growth Hormones Market Forecast 2017-2027
    • 5.4.2. Biosimilar Growth Hormones and Pen Injectors
    • 5.4.3. Uptake of Needle-Free Injectors for Growth Hormones
  • 5.5. The Vaccine Market Outlook 2017-2027
    • 5.5.1. Vaccine Market Forecast 2017-2027
    • 5.5.2. Single-Use Devices for Vaccine Delivery
      • 5.5.2.1. BD Uniject: A Private-Public Collaboration
    • 5.5.3. Needle-Free Injectors for Vaccines
    • 5.5.4. Other Trends in Vaccine Delivery
  • 5.6. PCSK9 Inhibitors: The Next Advance in Cholesterol-Lowering Drugs
    • 5.6.1. PCSK9 Inhibitors Market Forecast 2017-2027
    • 5.6.2. PCSK9 Inhibitors and Pre-Filled Syringes/Injectors

6. Leading Pre-Filled Device Therapies 2017-2027

  • 6.1. Leading Insulin Therapies Using Pen Injectors 2017-2027
    • 6.1.1. Lantus: The World's Best-Selling Insulin Analogue
      • 6.1.1.1. SoloSTAR, ClikSTAR and AllSTAR: Three Pen Injectors for Lantus
      • 6.1.1.2. Lantus: Sales Forecast 2017-2027
    • 6.1.2. NovoLog: The Leading Fast-Acting Insulin
      • 6.1.2.1. NovoLog FlexPen: To Be Retired
      • 6.1.2.2. Novo's New FlexTouch Pen Launched
      • 6.1.2.3. NovoLog: Sales Forecast 2017-2027
    • 6.1.3. Humalog
      • 6.1.3.1. Humalog: HumaPen and KwikPen
      • 6.1.3.2. Humalog: Sales Forecast 2017-2027
  • 6.2. Top Biologics for Rheumatoid Arthritis: Device Outlook to 2027
    • 6.2.1. Humira: The Biggest-Selling Drug in 2015
      • 6.2.1.1. The Humira Pen Is an Innovative Delivery Device
      • 6.2.1.2. Humira: Sales Forecast 2017-2027
    • 6.2.2. Enbrel: The Leading Competitor to Humira
      • 6.2.2.1. Pre-Filled Injection Devices Available for Enbrel in 2015
      • 6.2.2.2. Enbrel: Sales Forecast 2017-2027
  • 6.3. Growth Hormones: Two Products Dominated the Market in 2015
    • 6.3.1. Norditropin: the Leading Growth Hormone
      • 6.3.1.1. Norditropin: Sales Forecast 2017-2027
    • 6.3.2. Genotropin: Sales Forecast 2017-2027
  • 6.4. Outlook for Leading PCSK9 Products 2017-2027
    • 6.4.1. Praluent (alirocumab, Sanofi/Regeneron)
      • 6.4.1.1. Praluent: Sales Forecast 2017-2027
      • 6.4.1.2. Amgen Suit Against Sanofi/Regeneron's Praluent
    • 6.4.2. Repatha (evolocumab, Amgen)
      • 6.4.2.1. Repatha: Sales Forecast 2017-2027

7. Leading Pre-Filled Syringe and Related Technology Manufacturers, 2016

  • 7.1. Leading Pre-Filled Syringe Manufacturers market share in 2016
    • 7.1.1. Becton, Dickinson & Company: The Market Leader
      • 7.1.1.1. Becton, Dickinson & Company: Pre-Filled Syringes Product Portfolio
      • 7.1.1.2. BD Historical Revenue and Market Prospects
      • 7.1.1.3. Recent Acquisitions by BD
      • 7.1.1.4. BD Acquisition of CareFusion
      • 7.1.1.5. BD AutoShield Duo Pen Needle Launched in 2014
    • 7.1.2. Gerresheimer
      • 7.1.2.1. Gerresheimer: Pre-Filled Syringes Product Portfolio
      • 7.1.2.2. Gerresheimer Historical Revenue 2014-2015 and Market Outlook
      • 7.1.2.3. Gerresheimer: Expansion of Product Manufacturing Facility
      • 7.1.2.4. Gerresheimer: Products in Development
      • 7.1.2.5. Patent Application for Gerresheimer's Gx G-Fix Adapter
      • 7.1.2.6. Gerresheimer Commissioned to Manufacture Simponi Autoinjectors
      • 7.1.2.7. Gerresheimer Opens First Development Center in China
    • 7.1.3. Schott
      • 7.1.3.1. Schott: Pre-Filled Syringes Product Portfolio
      • 7.1.3.2. Schott Historical Revenue and Market Prospects
      • 7.1.3.3. Schott: Expansion in India
  • 7.2. Other Notable Pre-Filled Syringe Manufacturers
    • 7.2.1. Baxter: Providing Contract Manufacturing with Pre-Filled Syringes
    • 7.2.2. Nipro: Leading Japanese Contract Manufacturer
      • 7.2.2.1. Nipro's 2012 Acquisition of MGlas
    • 7.2.3. Stevanato Group/Ompi: Insulin Vials Market Leader
    • 7.2.4. Weigao: Pre-Filled Syringes for China and Beyond
    • 7.2.5. Unilife: Pre-Filled Safety Syringes
    • 7.2.6. Roselabs: Entered the Market in 2012
    • 7.2.7. Vetter Pharma: Offering Lyo-Ject Dual-Chamber Syringes
    • 7.2.8. Other Companies
  • 7.3. Leading Pen Injector and Autoinjector Manufacturers in 2015
    • 7.3.1. SHL Group
      • 7.3.1.1. SHL Group: Pen Injectors and Autoinjectors Product Portfolio
      • 7.3.1.2. SHL Group Market Prospects
    • 7.3.2. Ypsomed
      • 7.3.2.1. Ypsomed: Pen Injectors and Autoinjectors Product Portfolio
      • 7.3.2.2. Ypsomed Historical Revenue and Market Prospects
      • 7.3.2.3. Ypsomed: Recent Developments
    • 7.3.3. Haselmeier
      • 7.3.3.1. Haselmeier: Pen Injectors and Autoinjectors Product Portfolio
      • 7.3.3.2. Haselmeier: Market Prospects
    • 7.3.4. Owen Mumford
      • 7.3.4.1. Owen Mumford: Pen Injectors and Autoinjectors Product Portfolio
    • 7.3.5. Bespak: Entering the Auto-Injectors Market
    • 7.3.6. Other Leading and Emerging Autoinjector Manufacturers
  • 7.4. Leading Pre-Filled Syringe Component Manufacturers in 2016
    • 7.4.1. Datwyler
      • 7.4.1.1. Datwyler Historical Revenue and Market Prospects

8. Qualitative Analysis of the Pre-Filled Syringes Market 2017-2027

  • 8.1. SWOT Analysis of the Pre-Filled Syringes Market
  • 8.2. Strengths
    • 8.2.1. Pre-Filled Syringes and Pen/Autoinjectors are Used In Chronic Conditions
    • 8.2.2. Device Manufacturers Offer a Range of Products
    • 8.2.3. Customisation and Product Differentiation
    • 8.2.4. Effective Lifecycle Management
    • 8.2.5. Advantages associated with pre-filled syringes
  • 8.3. Weaknesses
    • 8.3.1. Patients with Needle Phobia
    • 8.3.2. Chronic Diseases May Make Pre-Filled Syringes Difficult to Use
    • 8.3.3. Risk of Extractables and Leachables
    • 8.3.4. Higher Cost and Greater Cold Chain and Storage Requirements
  • 8.4. Opportunities
    • 8.4.1. Biosimilars Represent a Growing Market
    • 8.4.2. Viscous and Large-Volume Drugs Require Novel Devices
    • 8.4.3. Technological Developments Expanding Product Portfolios
    • 8.4.4. Many Injectable Drugs in the Pipeline
    • 8.4.5. Growth in Emerging Markets
  • 8.5. Threats
    • 8.5.1. Alternative Technologies: Needle-Free and Bolus Injectors
    • 8.5.2. New Oral Therapies for Many Chronic Conditions
    • 8.5.3. Increasing Regulatory Barriers
    • 8.5.4. Cost Pressures on Healthcare Payers
  • 8.6. STEP Analysis of the Pre-Filled Syringes Market
    • 8.6.1. Social Factors: Rising Disease Incidence and Demand for At-Home Care
    • 8.6.2. Technological Developments: Improved Safety and Administration
    • 8.6.3. Economic Pressures: Pre-Filled Syringes Are Cost Efficient
      • 8.6.3.1. High Barriers to Market Entry Exist
    • 8.6.4. Political Issues: Regulatory Developments for Pre-Filled Syringes
  • 8.7. Regulatory and Safety Outlook for Pre-Filled Syringes, 2017-2027
    • 8.7.1. Needlestick Safety and Prevention
    • 8.7.2. International Regulations for Needlestick Prevention
      • 8.7.2.1. The US: The First Country to Introduce Needlestick Legislation
      • 8.7.2.2. The EU: New Rules from 2013 Onwards
      • 8.7.2.3. Needlestick Safety in Japan
      • 8.7.2.4. Legislation for Needlestick Safety in Emerging Markets
    • 8.7.3. Manufacturers Will Continue to Develop New Devices for Needlestick Prevention
      • 8.7.3.1. Ancillary versus Integrated Safety Devices
    • 8.7.4. Extractables and Leachables
      • 8.7.4.1. Companies Will Reduce Sources of Extractables and Leachables
      • 8.7.4.2. Products that Minimise Extractables and Leachables
      • 8.7.4.3. Protein Aggregation: The Challenge of Biological Drugs
      • 8.7.4.4. Regulatory Requirements for Extractables and Leachables
  • 8.8. Biologics and the Pre-Filled Syringes Market, 2017-2027
    • 8.8.1. Manufacturing Pre-Filled Syringes for Biologics: Glass versus Plastic
    • 8.8.2. Biologics Provide New Challenges for Device Manufacturers
      • 8.8.2.1. Lyophilised Drugs and Dual-Chamber Devices
    • 8.8.3. Delivery Opportunities for High Viscosity Drugs
    • 8.8.4. Are Biosimilars an Opportunity for Pre-Filled Syringe Manufacturers?
  • 8.9. The Role of Patients in Pre-Filled Syringe Industry Development and Growth
    • 8.9.1. Chronic Disease Incidence 2017-2027
    • 8.9.2. The Rise in At-Home Care
    • 8.9.3. Improving Patient Adherence
    • 8.9.4. Injection Devices Must be Developed for Patient Convenience: Human Factors Engineering
  • 8.10. Technological Developments in Pre-Filled Syringes to 2027
    • 8.10.1. Product Differentiation Will be Vital in Crowded Treatment Markets
    • 8.10.2. Product Customisation: Adapting Injection Devices
    • 8.10.3. Trends in Manufacturing Materials for Pre-Filled Syringes
    • 8.10.4. Competing Technologies Will Challenge Pre-Filled Syringes
      • 8.10.4.1. Will Needle-Free Devices Become a Significant Competing Technology?
      • 8.10.4.2. Patients Prefer Oral Drug Delivery
  • 8.11. Outsourcing in the Pre-Filled Syringe Industry
    • 8.11.1. Contract Medical Device Manufacturing
    • 8.11.2. Contract Filling of Pre-Filled Syringes

9. Conclusions

  • 9.1. Pre-Filled Syringes and Pen/Autoinjectors: Strong Growth Expected
  • 9.2. The World Pre-Filled Syringes Market in 2016
    • 9.2.1. Current Leading Pre-Filled Syringes Segments
    • 9.2.2. Leading Pre-Filled Syringes Companies
    • 9.2.3. Leading National and Regional Markets
  • 9.3. World Pre-Filled Syringes Market Forecast 2017-2027
  • 9.4. The Future of the Pre-Filled Syringes Market?
    • 9.4.1. Glass Syringes Will Continue to Dominate
    • 9.4.2. Innovation for Growth

10. Glossary

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 3.1: World Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Segment, 2016-2027
  • Table 3.2: Market Shares (%) of Leading Pre-Filled Syringes Market Segments, by Revenue, 2016, 2021 and 2027
  • Table 3.3: Glass Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 3.4: Selected Proprietary Polymers for Plastic Pre-Filled Syringes, 2016
  • Table 3.5: Plastic Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 3.6: Pen Injectors and Autoinjectors Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.1: World Pre-Filled Syringes Market: Revenues ($m) and Market Shares (%) by National Market, 2016
  • Table 4.2: World Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2016-2027
  • Table 4.3: Market Shares (%) of Leading National Pre-Filled Syringes Markets, 2016, 2021 and 2027
  • Table 4.4: World Pre-Filled Syringes Market: Revenues ($m) and Market Shares (%) by Regional Market, 2016
  • Table 4.5: World Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2027
  • Table 4.6: Market Shares of Leading Regional Pre-Filled Syringes Markets, 2016, 2021 and 2027
  • Table 4.7: US Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2027
  • Table 4.8: Japanese Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.9: EU5 Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2016-2027
  • Table 4.10: Chinese Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.11: Indian Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.12: Russian Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.13: Brazilian Pre-Filled Syringes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 5.1: Pen Manufacturing Agreements for Leading Insulin Brand Manufacturers, 2015
  • Table 5.2: Selected Biosimilar Insulin Pen Injectors, 2017
  • Table 5.3: Insulin Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 5.4: Rheumatoid Arthritis Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 5.5: Growth Hormone Therapies in Pen Injectors, 2016
  • Table 5.6: Growth Hormones Market Forecast: Revenues ($m), AGR and CAGR, 2016-2027
  • Table 5.7: Selected Biosimilar Growth Hormones in Emerging Markets, 2016
  • Table 5.8: Vaccines Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 5.9: PCSK9 Inhibitors Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.1: Leading Pre-Filled Insulin Therapies: Revenues ($m), AGR (%) and CAGR (%), 2010-2016
  • Table 6.2: Sanofi: Lantus Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.3: Novo Nordisk: NovoLog Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.4: Eli Lilly: Humalog Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.5: Leading Pre-Filled Rheumatoid Arthritis Therapies: Revenues ($m), AGR (%) and CAGR (%), 2010-2015
  • Table 6.6: AbbVie/Eisai: Humira Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.7: Amgen/Pfizer: Enbrel Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.8: Leading Pre-Filled Growth Hormone Therapies: Revenues ($m), AGR (%) and CAGR (%), 2010-2015
  • Table 6.9: Novo Nordisk: Norditropin Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.10: Pfizer: Genotropin Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.11: Sanofi: Praluent Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.12: Amgen: Repatha Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 7.1: BD: Overview, 2016
  • Table 7.2: BD: Pre-Filled Injection Systems, 2016
  • Table 7.3: BD: Pharmaceutical Systems Revenue ($m), AGR (%), CAGR (%), 2010-2015
  • Table 7.4: Gerresheimer: Overview, 2016
  • Table 7.5: Gerresheimer: Plastics & Devices and Primary Packaging Glass Segment Revenue ($m) for 2015 and 2016, plus AGR (%)
  • Table 7.6: Schott: Overview, 2017
  • Table 7.7: Schott: Net Revenue ($m), AGR (%) and CAGR (%), 2010-2015
  • Table 7.8: Unilife: Pre-Filled Syringe Product Portfolio, 2016
  • Table 7.9: Unilife: Net Revenue ($m), AGR (%) and CAGR (%), 2010-2015
  • Table 7.10: SHL Group: Overview, 2016
  • Table 7.11: SHL Group: Pen Injector and Autoinjector Portfolio, 2016
  • Table 7.12: Ypsomed: Overview, 2016
  • Table 7.13: Ypsomed: Pen Injector and Autoinjector Portfolio, 2016
  • Table 7.14: Ypsomed: Delivery Devices Revenue ($m), AGR (%) and CAGR (%), 2010-2015
  • Table 7.15: Haselmeier: Overview, 2016
  • Table 7.16: Haselmeier: Pen Injector and Autoinjector Portfolio, 2016
  • Table 7.17: Owen Mumford: Overview, 2016
  • Table 7.18: Owen Mumford: Pen Injector and Autoinjector Portfolio, 2016
  • Table 7.19: Datwyler: Overview, 2016
  • Table 7.20: Datwyler: Pharma Packaging Revenue ($m), AGR (%) and CAGR (%), 2010-2015
  • Table 8.1: Benefits and Weaknesses to Pre-Filled Syringes as an Injectable Delivery Device, 2017
  • Table 8.2: Pre-Filled Syringes Market: STEP Analysis, 2017-2027
  • Table 8.3: Selected Safety Products for Pre-Filled Syringes, 2016
  • Table 8.4: Selected Pre-Filled Injection Devices for Lyophilised Drugs, 2016
  • Table 8.5: Pre-Filled Syringe Manufacturers: Alternative Injectable Technologies, 2016
  • Table 8.6: Selected Insulin Pumps Available, 2016
  • Table 8.7: Oral Drug Competitors for Leading Pre-Filled Syringe Therapeutic Sectors, 2017-2027
  • Table 8.8: Selected Leading CMOs: Pre-Filled Syringe Filling Capabilities, 2016

List of Figures

  • Figure 1.1: Global Pre-Filled Syringes Market Segmentation Overview, 2017
  • Figure 2.1: Diagram of Syringe Parts
  • Figure 2.2: Timeline of Pre-Filled Syringe Development, 1950-2015
  • Figure 2.3: Major Trends for Pre-Filled Syringe Market Growth, 2017
  • Figure 3.1: World Pre-Filled Syringes Market: Market Shares (%) by Segment, 2016
  • Figure 3.2: World Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 3.3: World Pre-Filled Syringes Market by Revenue: Market Shares (%) by Segment, 2016
  • Figure 3.4: World Pre-Filled Syringes Market by Revenue: Market Shares (%) by Segment, 2021
  • Figure 3.5: World Pre-Filled Syringes Market by Revenue: Market Shares (%) by Segment, 2027
  • Figure 3.6: World Pre-Filled Syringes Market: Drivers and Restraints, 2017-2027
  • Figure 3.7: Glass Pre-Filled Syringes Market Forecast: Revenues ($m), 2016-2027
  • Figure 3.8: Glass Pre-Filled Syringes Market: Drivers and Restraints, 2017-2027
  • Figure 3.9: Plastic Pre-Filled Syringes Market Forecast: Revenues ($m), 2016-2027
  • Figure 3.10: Plastic Pre-Filled Syringes Market: Drivers and Restraints, 2017-2027
  • Figure 3.11: Pen Injectors and Autoinjectors Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 3.12: Pen Injectors and Autoinjectors Market: Drivers and Restraints, 2017-2027
  • Figure 4.1: World Pre-Filled Syringes Market: Revenues ($m) by National Market, 2016
  • Figure 4.2: World Pre-Filled Syringes Market: Market Shares (%) by National Market, 2016
  • Figure 4.3: World Pre-Filled Syringes Market: Market Shares (%) by National Market, 2021
  • Figure 4.4: World Pre-Filled Syringes Market: Market Shares (%) by National Market, 2027
  • Figure 4.5: World Pre-Filled Syringes Market: Revenues ($m) by Regional Market, 2016
  • Figure 4.6: World Pre-Filled Syringes Market: Market Shares (%) by Regional Market, 2016
  • Figure 4.7: World Pre-Filled Syringes Market: Market Shares (%) by Regional Market, 2021
  • Figure 4.8: World Pre-Filled Syringes Market: Market Shares (%) by Regional Market, 2027
  • Figure 4.9: US Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 4.10: Japanese Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 4.11: EU5 Pre-Filled Syringes Market Forecast: Revenues ($m) by National Market, 2016-2027
  • Figure 4.12: Chinese Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 4.13: Indian Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 4.14: Russian Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 4.15: Brazilian Pre-Filled Syringes Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 5.1: Insulin Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 5.2: Rheumatoid Arthritis Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 5.3: Growth Hormones Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 5.4: Vaccines Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 5.5: PCSK9 Inhibitors Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 6.1: Sanofi: Lantus Revenue ($m) and AGR (%), 2016-2027
  • Figure 6.2: Novo Nordisk: NovoLog Revenue ($m) and AGR (%), 2016-2027
  • Figure 6.3: Eli Lilly: Humalog Revenue ($m) and AGR (%), 2016-2027
  • Figure 6.4: AbbVie/Eisai: Humira Revenue ($m) and AGR (%), 2016-2027
  • Figure 6.5: Amgen/Pfizer: Enbrel Revenue ($m) and AGR (%), 2016-2027
  • Figure 6.6: Novo Nordisk: Norditropin Revenue ($m) and AGR (%), 2016-2027
  • Figure 6.7: Pfizer: Genotropin Revenue ($m) and AGR (%), 2016-2027
  • Figure 6.8: Sanofi/Regeneron: Praluent Revenue ($m) and AGR (%), 2016-2027
  • Figure 6.9: Amgen: Repatha Revenue ($m) and AGR (%), 2016-2027
  • Figure 7.1: Global Pre-filled syringes market market share in 2016
  • Figure 7.2: BD: Pharmaceutical Systems Revenue ($m), AGR (%), 2010-2015
  • Figure 7.3: Gerresheimer: Plastics & Devices and Primary Packaging Glass Segment Revenue ($m), 2015 and 2016
  • Figure 7.4: Schott: Net Revenue ($m) and AGR (%), 2010-2015
  • Figure 7.5: Unilife: Net Revenue ($m) and AGR (%), 2010-2015
  • Figure 7.6: Ypsomed: Delivery Devices Revenue ($m) and AGR (%), 2010-2015
  • Figure 7.7: Datwyler: Pharma Packaging Revenue ($m) and AGR (%), 2010-2015
  • Figure 8.1: Pre-Filled Syringes Market: Strengths and Weaknesses, 2017-2027
  • Figure 8.2: Pre-Filled Syringes Market: Opportunities and Threats, 2017-2027
  • Figure 9.1: World Pre-Filled Syringes Market Forecast: Revenues ($m) by Segment, 2016-2027

Companies Listed

  • AbbVie
  • Ache
  • Amega Biotech
  • Amgen
  • Antares Pharma
  • Aptar Stelmi
  • AstraZeneca
  • Baxter International
  • Becton, Dickinson and Company
  • Bespak
  • Biocon
  • Bioject Medical Technologies
  • Biomarin
  • Biosidus
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cambridge Consultants
  • CareFusion Corporation
  • Celgene
  • Centocor
  • Daikyo Seiko
  • Datwyler
  • Dong-A
  • Dr. Reddy's
  • Eisai Pharmaceutical
  • Eli Lilly
  • Ferring
  • Gan & Lee
  • GeneScience Pharmaceuticals
  • Gerresheimer
  • GlaxoSmithKline
  • Haselmeier
  • Helvoet Pharmaceutical
  • Hospira
  • Incepta Pharmaceuticals
  • Janssen Biotech
  • Johnson and Johnson
  • LG Life Sciences/Biopartners
  • Mannkind
  • Merck & Co
  • Merck Serono
  • Mitsubishi Tanabe
  • Nektar Therapeutics
  • Nipro
  • Novartis
  • Novo Nordisk
  • OPKO Health
  • Oval Medical
  • Owen Mumford
  • PA Consulting Group
  • Palatin Technologies
  • Pfizer
  • PharmaJet
  • Pharmstandard
  • Polfa Tarchomin
  • Regeneron
  • Rhone Poulenc-Rorer
  • Roehr Products
  • Roselabs Bioscience
  • Samsung Bioepis
  • Sandoz
  • Sanofi
  • Schott
  • Schott Kaisha
  • Schott Xinkang Pharmaceutical Packaging
  • SciGen
  • Shanghai Celgen Bio-Pharmaceutical
  • Shanghai CP Guojin
  • SHL Group
  • Square Pharmaceuticals
  • Stevanato Group (Ompi)
  • Takeda Pharmaceutical
  • Terumo
  • Teva Pharmaceutical
  • Tonghua Dongbao
  • UCB
  • Unlife
  • Vetter
  • Vetter Pharma
  • Weigao
  • West Pharmaceuticals
  • Wockhardt
  • Ypsomed
  • Zeon

Organisations Mentioned in the Report

  • Battele Memorial Institute
  • Carl Zeiss Foundation
  • Centers for Disease Control (US)
  • European Society of Cardiology
  • National Health Service (UK)
  • Parenteral Drug Association
  • PATH
  • UNICEF
  • US Agency for International Development
  • US Federal Drug Administration
  • World Health Organization
Back to Top